1. Home
  2. ULTA vs RPRX Comparison

ULTA vs RPRX Comparison

Compare ULTA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ulta Beauty Inc.

ULTA

Ulta Beauty Inc.

N/A

Current Price

$638.15

Market Cap

23.8B

ML Signal

N/A

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

N/A

Current Price

$45.81

Market Cap

19.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ULTA
RPRX
Founded
1990
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8B
19.4B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
ULTA
RPRX
Price
$638.15
$45.81
Analyst Decision
Buy
Strong Buy
Analyst Count
26
4
Target Price
$615.33
$47.75
AVG Volume (30 Days)
402.9K
3.2M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
2.07%
EPS Growth
N/A
N/A
EPS
17.65
1.78
Revenue
$11,295,654,000.00
$2,378,193,000.00
Revenue This Year
$11.37
$38.30
Revenue Next Year
$6.07
$4.80
P/E Ratio
$36.60
$25.56
Revenue Growth
0.79
5.06
52 Week Low
$309.01
$29.66
52 Week High
$714.97
$47.86

Technical Indicators

Market Signals
Indicator
ULTA
RPRX
Relative Strength Index (RSI) 38.21 59.36
Support Level $624.95 $35.32
Resistance Level $691.17 $46.14
Average True Range (ATR) 18.79 0.89
MACD -6.97 -0.17
Stochastic Oscillator 22.19 35.64

Price Performance

Historical Comparison
ULTA
RPRX

About ULTA Ulta Beauty Inc.

Ulta Beauty is the largest specialized beauty retailer in the US with about 1,500 freestanding stores. The firm offers cosmetics (39% of 2024 sales), fragrances (13%), skin care (23%), and hair care products (19%). It also has salon services, including hair, makeup, skin, and brow, that account for about 4% of its revenue and drive traffic. Outside of the US, Ulta acquired premium beauty retailer Space NK and its 83 stores in the UK and Ireland in 2025, is opening franchised stores in Mexico, and has formed a joint venture to expand into the Middle East. In addition, Ulta collects royalties through its Target partnership (set to end in 2026) and credit card revenue. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: